Specialty Pipeline Update
|
|
- Alicia Bell
- 5 years ago
- Views:
Transcription
1 Specialty Pipeline Update D Drug Insights > March New drug information Xermelo (telotristat etiprate): The U.S. Food and Drug Administration (FDA) granted approval of Lexicon s Xermelo tablets for the treatment of adults with carcinoid syndrome diarrhea that somatostatin analogues (SSA) therapy alone has inadequately controlled. Carcinoid syndrome occurs in people with carcinoid tumors which are rare. Carcinoid syndrome occurs in less than 10 percent of patients with carcinoid tumors. SSAs control carcinoid syndrome in 80 percent of patients. 2, 3 In a 12-week trial, 33 percent of patients randomized to add Xermelo on to SSA therapy experienced an average reduction of 2 bowel movements per day compared to 4 percent of patients taking SSA alone. 1 Xermelo must be taken 3 times daily with food. Kisqali (ribociclib): The FDA approved Novartis Kisqali in combination with an aromatase inhibitor as initial endocrinebased therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This will compete with Pfizer s Ibrance (palbociclib) which has the same mechanism of action and indication. Novartis anticipates Kisqali will have a percent lower aggregate cost than Ibrance due to Kisqali s flexible pricing structure. 4 Although Kisqali may cost less than Ibrance, use of Kisqali requires ECG monitoring which is not a requirement with Ibrance use. New indications Revlimid (lenalidomide): Celgene received a new indication for maintenance treatment of newly diagnosed multiple myeloma (MM) patients after receiving autologous stem cell transplant. Prior to this indication, Revlimid was approved for use in MM in combination with dexamethasone, transfusion-dependent anemia due to low- or intermediate- 1 risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities, and mantle cell lymphoma whose disease has relapsed or progressed after 2 prior therapies, one of which included bortezomib. Keytruda (pembrolizumab): Merck received a new indication for the treatment of patients with refractory classical Hodgkin lymphoma, or who have relapsed after 3 or more prior lines of therapy. This indication was approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. While the information in this newsletter is from sources we believe to be reliable, we do not warrant that the information in this document is free from error. Use it only as a guide. Statements regarding drugs or manufacturers are not intended as promotion; those statements should not be used to make assumptions about formulary status. Each trademarked drug name is the property of its respective owner.
2 Specialty Pipeline > March Page 2 March news The FDA accepted Mylan and Biocon s Herceptin biosim application and set a regulatory decision deadline for Sept. 3,. With that news, plus a new settlement agreement, Mylan says it could reach the lucrative U.S. market before any other competitor. 5 The FDA has informed Radius Health that it will require additional time to complete its review of the company s new drug application (NDA) for abaloparatide-sc. The agency extended the Prescription Drug User Fee Act (PDUFA) action date to June 30,. In its letter, the FDA did not request any additional information from Radius. 6 Regeneron and Sanofi s Dupixent showed positive results in a one-year study in which patients receiving the drug achieved significantly improved clearance of skin lesions and reduction of overall disease severity compared with topical corticosteroids alone in adults with moderate-to-severe atopic dermatitis or eczema. 7 AstraZeneca s Lynparza honed its edge in ovarian cancer, and just in time to help preserve its lead in the marketplace. In detailed results from a test of the drug in patients who d relapsed after platinum chemo, the first-in-class PARP inhibitor held off cancer recurrence by more than two years, compared with placebo, and delivered a statistically significant improvement in the risk of tumor progression or death. Those numbers compare favorably with Tesaro s competitor niraparib, which delivered a 15.5-month survival advantage in its own maintenance-therapy trial. 9 Results from the long-awaited Fourier trial, designed to test Amgen s Repatha as a tool to cut cardiovascular risks, showed that the drug cut heart attack risks by 27% over the course of the study, which followed patients for an average of two years. It cut the risk of stroke by 21%. 10 PTC Therapeutics Inc said on Thursday it would buy Marathon Pharmaceuticals LLC s recently approved Duchenne muscular dystrophy drug, Emflaza, and promised to re-examine the hefty U.S. price tag on the treatment. Emflaza is available outside the United States as a generic to treat the devastating muscle-wasting genetic disease that mainly affects young boys. Last month, the U.S. Food and Drug Administration approved Marathon selling Emflaza in the United States. 8
3 Specialty Pipeline > March Page 3 Specialty new product approvals in the past 12 months Generic name Brand name Manufacturer Indication(s) Route of administration Date approved* telotristat etiprate Xermelo Lexicon Carcinoid syndrome Oral February brodalumab Siliq Valeant Plaque psoriasis Subcutaneous February injection immune globulin Gammaplex 10% Bio Products Primary immunodeficiency/ chronic immune thrombocytopenic purpura IV February deflazacort Emflaza Marathon Pharmaceuticals Duchenne muscular dystrophy (DMD) Oral February etelcacetide Parsabiv Amgen Secondary February hyperparathyroidism nusinersen Spinraza Ionis/Biogen Spinal muscular atrophy (SMA) Intrathecal December 2016 bezlotoxumab Zinplava Merck Reduce recurrence of Clostridium difficile infection adalimumab-otto Amjevita Amgen Biosimilar to Humira (adalimumab): 7 inflammatory diseases eteplirsen Exondys 51 Sarepta Therapeutics Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation in the DMD gene that is amenable to exon 51 skipping immune globulin (human), 20% solution Cuvitru Shire/Baxalta To treat adults and pediatric patients ages 2 years and older with primary immunodeficiency etanercept-szzs Erelzi Sandoz Biosimiliar to Enbrel (etanercept) all indications Subcutaneous Subcutaneous injection October August 2016 Launch delayed until late 2018 or beyond. sofosbuvir/velpatasvir Epclusa Gilead Hepatitis C (all genotypes) Oral June 2016 daclizumab high-yield process Zinbryta Biogen and AbbVie Multiple sclerosis Subcutaneous injection obeticholic acid Ocaliva Intercept Primary biliary cholangitis Oral recombinant factor VIII single chain Afstyla CSL Behring Hemophilia A infliximab Remsima Celltrion/Pfizer Biosimilar to Remicade April 2016 emtricitabine/tenofovir alafenamide Descovy Gilead HIV Oral April 2016
4 Specialty Pipeline > March Page 4 New indications for approved specialty products Generic name Brand name Manufacturer Indication(s) Date approved* ranibizumab Lucentis Genentech Myopic choroidal neovascularization (mcnv) February 2016 Factor VIII, recombinant, pegylated Adynovate Shire Pediatric hemophilia A patients who are 12 years old and younger, as well as for use in surgical settings for children and adults etanercept Enbrel Amgen Pediatric patients 4 years or older with chronic moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy; prior to this approval only adults aged 18 years and older were approved for this indication canakinumab Ilaris Novartis Tumor necrosis factor-receptor associated periodic syndrome (TRAPSS), hyperimmunoglobulin D syndrome (HIDS)/ mevalonate kinase deficiency (MKD), and familial Mediterranean fever (FMF) lumacaftor/ivacaftor Orkambi Vertex Pharmaceuticals Treatment of cystic fibrosis in patients 6 years and older who are homozygous for the F508del mutation in the CFTR gene abobotulinumtoxina Dysport Ipsen Biopharmaceuticals ombitasvir, paritaprevir, ritonavir, dasabuvir To treat lower limb spasticity in pediatric patients ages 2 years and older Viekira XR AbbVie, Enanta New once-daily formulation of the directacting antiviral combination for treatment of chronic hepatitis C virus 1 in patients with or without compensated cirrhosis and is used in combination with twice-daily ribavirin for genotype 1a patients and without ribavirin for genotype 1b patients December 2016 October 2016 October 2016 August 2016 July 2016 C1 esterase inhibitor [human] Berinert CSL Bering To treat hereditary angioedema (HAE) attacks in July 2016 pediatric patients darunavir Prezista Janssen To treat HIV infection in pregnant women July 2016 evolocumab Repatha Amgen 420 mg once monthly dose administered as a single injection omalizumab Xolair Roche For the treatment of moderate-to-severe persistent asthma in children ages 6 through 11 adalimumab Humira AbbVie For patients with non-infectious intermediate, posterior, and panuveitis alpha-1 proteinase inhibitor [human] Glassia Shire and Kamada Self-administration indication (alpha 1-antitrypsin deficiency in people who have symptoms of emphysema) July 2016 July 2016 July 2016 June 2016
5 Specialty Pipeline > March Page 5 Oncology product approvals in the past twelve months Generic Name Brand Name Manufacturer Indication(s) Route of Administration Date Approved ribociclib Kisqali Novartis Breast cancer Oral March 2016 rucaparib Rubraca Clovis Ovarian cancer Oral December 2016 oloaratumab Lartruvo Lilly Soft tissue sarcoma atezolizumab Tecentriq Roche Metastatic urothelial bladder cancer cabozantinib Cabometyx Exelixis Advanced renal cell carcinoma Oral April 2016 venetoclax Venclexta AbbVie/Genentech Chronic lymphocytic leukemia (CLL) Oral April 2016 New indications for approved oncology drugs Generic name Brand name Manufacturer New Indication(s) Date approved* pembrolizumab Keytruda Merck Refractory classical Hodgkin lymphoma March lenalidomide Revlimid Celgene Maintenance treatment of newly diagnosed multiple myeloma patients after receiving autologous stem cell transplant (ASCT) nivolumab Opdivo Bristol Patients with locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy ibrutinib Imbruvica Janssen Marginal zone lymphoma (MZL) who require systemic therapy bevacizumab Avastin Genetech In combination with chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer daratumumab Darzalex Janssen In combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy nivolumab Opdivo BMS To treat metastatic or recurrent squamous cell carcinoma of the head and neck following disease progression on or after platinum-based therapy pembrolizumab Keytruda Merck For the treatment of patients with metastatic NSCLC whose tumors express PD-L1 as determined by an FDA-approved test. This approval also expands the indication in secondline treatment of lung cancer to include all patients with PD-L1-expressing NSCLC erlotinib Tarceva Genetech For metastatic non-small cell lung cancer (NSCLC) to limit use to patients whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least 1 prior chemotherapy regimen February February January December 2016 continued
6 Specialty Pipeline > March Page 6 Generic name Brand name Manufacturer New Indication(s) Date approved* atezolizumab Tecentriq Roche Treatment of patients with metastatic non-small October 2016 cell lung cancer (NSCLC) who have progressed during or following platinum-containing chemotherapy blinatumomab Blincyto Amgen For the treatment of pediatric and adolescent August 2016 patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) ofatumumab Arzerra Novartis, Genmab For the anti-cd20 monoclonal antibody for August 2016 use in combination with fludarabine and cyclophosphamide for treatment of patients with relapsed chronic lymphocytic leukemia (CLL) pembrolizumab Keytruda Merck For head and neck cancer August 2016 nivolumab Opdivo Bristol-Myers Squibb For treatment of classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and posttransplantation brentuximab vedotin (Adcetris) lenvatinib Lenvima Eisai For patients with advanced renal cell carcinoma who were previously treated with an antiangiogenic therapy ibrutinib Imbruvica AbbVie and Johnson & Johnson For use in combination with bendamustine and Rituxan (rituximab) for treatment of relapsed or refractory chronic lymphocytic leukemia and small lymphocytic leukemia afatinib Gilotrif Boehringer Ingelheim For patients with advanced squamous cell carcinoma of the lung with progression after firstline chemotherapy April 2016
7 Specialty Pipeline > March Page 7 Pipeline watch Generic Name Brand Name Manufacturer Indication(s) Route of Administration Anticipated Approval date* HIV vaccine Remune Immune Response HIV Intramuscular February SB2 Biosimilar of Remicade Samsung Bioepis and Merck Rheumatoid arthritis, Crohn s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis April 2016 baricitinib Olumiant Lilly and Incyte Rheumatoid arthritis Oral April brigatinib N/A Ariad Pharmaceuticals Non-small cell lung cancer Oral April valbenazine Ingrezza Neurocrine Biosciences Tardive dyskinesia Oral April deutetrabenazine N/A Teva Chorea associated with Oral April Huntington disease cerliponase alfa Brineura BioMarin Batten disease Intracerebroventricular April midostaurin N/A Novartis AML Oral May binimetinib N/A Array BioPharma Melanoma Oral June niraparib N/A Tesaro Recurrent ovarian/fallopian Oral June tube/primary peritoneal cancer nonacog beta pegol (Factor IX, N/A Novo Nordisk Hemophilia B May recombinant glyco-pegylated) C1-estrase inhibitor N/A CSL Bering Hereditary angioedema Subcutaneous June rituximab N/A Genetech/Roche NHL/CLL Subcutaneous June-July filgrastim Grastofil Apotex Neutropenia Subcutaneous June peg-filgrastim Lapelga Apotex Neutropenia Subcutaneous June peg-filgrastim N/A Coherus BioSciences Neutropenia Subcutaneous June sarilumab Kevzara Sanofi/Regeneron Rheumatoid arthritis Subcutaneous 2Q neratinib Puma Biotech/ Pfizer Breast cancer Oral July Pfizer enasidenib N/A Celegene/Agios R/R AML Oral August sofosbuvir, velpatasvir and N/A Gilead Hepatitis C Oral August voxilaprevir glecaprevir/pibrentasvir N/A AbbVie Hepatitis C Oral August sirukumab N/A GSK/Janssen Biotech Rheumatoid arthritis Subcutaneous eptacog beta, activated (Factor VIIa) N/A revo Biologics/LFB Hemophilia A or B with inhibitors adalimumab N/A Boehringer Ingelheim Arthritis, plaque psoriasis, ankylosing spondylitis, Crohn s disease, and ulcerative colitis trastuzumab N/A Mylan/Biocon HER2-positive breast and gastric cancers bevacizumab N/A Amgen NSCLC, colon cancer *Anticipated approval dates are predictions made by Prime Therapeutics based on industry information.
8 Specialty Pipeline > March Page 8 Watch list Criteria for inclusion on the watch list include: Drug is submitted to the FDA and is anticipated to have material impact to trend and/or material impact to preferred product strategies (medical or pharmacy). Brand (generic)/ manufacturer Ocrevus (ocrelizumab)/ Genentech Dupixent (dupilumab)/ Regeneron/Sanofi Proposed indication/route of administration Primary progressive multiple sclerosis (PPMS) and relapsing remitting multiple sclerosis (RRMS) (IV) Atopic dermatitis (AD)/ subcutaneous injection Anticipated approval (PDUFA date) Similar products (by indication) Spend* Net new impact to PMPM* pharmacy benefit March None for PPMS $$ None $$ Net new impact to PMPM* medical benefit March None $$ $$$ $$ $$$ None Ingrezza (valbenazine) Tardive dyskinesia (TD)/oral April Xenazine [0ff-label] $ $$ $ $$ None Radicava (edaravone)/ Mitsubishi Tanabe Pharma niraparib/tesaro Pharmaceutical grade L-glutamine (PGLG)/ Emmaus Life Science Translarna (ataluren)/ PTC Therapeutics Amyotrophic lateral sclerosis (ALS)/IV Recurrent ovarian/fallopian tube/primary peritoneal cancer/oral June Rilutek (riluzole) $$ None $$ June None $$ $$ None Sickle cell disease/oral July L-glutamine OTC/ Hydrea $ $$ $ $$ None Nonsense mutation Duchenne muscular dystrophy (nmdmd)/ oral October None $$ $$$ $$ $$$ None Orphan Drugs, evaluated for Watch List, do not meet criteria deutetrabenazine (SD-809)/Teva Brineura (cerliponase alfa) CSL830 (C1-estrase inhibitor)/csl Bering amantadine XR/Adamas Chorea associated with Huntington disease (HD)/oral CLN2 Disease, a form of Batten disease/ intracerebro-ventricular Prevention of hereditary angioedema attacks/sc Levodopa-induced dyskinesia (LID)/oral April Xenazine Switch therapy: Assume patients will switch from Xenazine to deutetrabenazine None April None $ None $ June Berinert, Cinryze, Ruconest August None by indication [amantadine IR, offlabel] Switch therapy: Spend may shift from medical to pharmacy due to SC dosing Switch therapy: Assume patients will switch from amantadine IR *Notations: $ < $0.08 per member per month (PMPM), $$ = $0.08 $0.39 PMPM, $$$ = $0.40 $2.00 PMPM, $$$$ > $2.01 PMPM. None
9 Specialty Pipeline > March Page 9 References Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology 2005 May; 128(6): Kvols LK, Moertel CG, O Connell MJ, et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. NEJM 1986; 315 (11): tok=eyjpijoitw1rmu9xvmlavgd6wwpsacisinqioijkrjj3z282vvzvzctlwwpsexdrrtfsmgfjays5cwtidstjd1jwu0dkwwnlmgfrsu5xogrrwdirt1vvr3lrbuxsk094cfwvsxn3cghss0zdr2lwbkrqtxrvsmxgm3rco FhMZ0FhbHIydzZta2FxeEZnUjY2RTJvNG1aSXhiOGk3anIifQ%3D%3D&mrkid= &utm_medium=nl&utm_source=internal NcL3Q0MDJaYkxiVDluZWl5UmNIVE1lbGtNSVB5cysySlVKbVpoTGpsRFAycXdHRVltRzhhdTJQTlZGbk1sNThoZ0RpMGRrZk9uR3NZY01cL0RubXp4d09ib3kydytZMEJYWElHaTEwbHVPIn0%3D&mrkid= &utm_ medium=nl&utm_source=internal kpnqmxjwvfgne8wzvuxcnr0rg1vy0v2u05xofh2rkrsy3llc1llnfzsrfmwnmdfrjdqavjfaknwdfhungdutultedlwqlbgrlvyqzkzzfjivtfqvfzgdgptdtc2ogx0thndxc8ifq%3d%3d&mrkid= &utm_medium=nl&utm_ source=internal. All brand names are property of their respective owners B1 Prime Therapeutics LLC 03/17
Specialty Pipeline Update
Specialty Pipeline Update D Drug Insights > December 2016 New drug information Rubraca (rucaparib): The U.S. Food and Drug Administration (FDA) granted accelerated approval to Clovis Oncology, Inc. s Rubraca
More informationSpecialty Pipeline Monthly Update
Specialty Pipeline Monthly Update Critical updates in an ever changing environment June 2017 New drug information Kevzara (sarilumab): Sanofi/Regeneron Pharmaceuticals received Food and Drug Administration
More informationSpecialty Pipeline Monthly Update
Specialty Pipeline Monthly Update Critical updates in an ever changing environment September 2017 New drug information Gocovri (amantadine HCl XR): The U.S. Food and Drug Administration (FDA) approved
More informationCENTENE PHARMACY & THERAPEUTICS COMMITTEE THIRD QUARTER 2017 NEW DRUG ARRIVALS SUMMARY TABLE. Utilization Management Recommendation
RT 1,2, 3,5 Drug Name 1 Brigatinib (Alunbrig ) 1 Deutetrabenazine (Austedo ) 1 Cerliponase alfa (Brineura ) Review Reason FDA-Approved (s) Alunbrig is indicated patients with anaplastic lymphoma kinase
More informationSession 169 L, Quantifying Excess Specialty Drug Risk. Moderator: Patrick Gallagher, FSA, FCAS. Presenters: Robert Bachler, FSA, FCAS, MAAA
Session 169 L, Quantifying Excess Specialty Drug Risk Moderator: Patrick Gallagher, FSA, FCAS Presenters: Patrick Gallagher, FSA, FCAS Robert Bachler, FSA, FCAS, MAAA SOA Antitrust Disclaimer SOA Presentation
More informationAdded, Removed or Changed. Date of Change. No Change
One mission: you s September 7, 2017 Blue Cross of Idaho reviews its formularies (covered drug lists) periodically to allow members access to new drugs and to provide safe, cost effective options for your
More informationNew Drugs of ,3,5,7,10,14,16,20,22,24,26,28,30,32,34,36,38,40,41,43,45-86 Brand Name/ Generic Name/ Approved Indication
1 New Drugs of 2017 1,3,5,7,10,14,16,20,22,24,26,28,30,32,34,36,38,40,41,43,45-86 Brand Name/ Generic Name/ Approved Indication Company Aliqopa Copanlisib Dihydrochloride Intravenous Bayer HealthCare Pharmaceuticals
More informationNICE TECHNOLOGY APPRAISAL MEDICINES REPORT 2017
NICE TECHNOLOGY PPRISL MEDICINES REPORT St George s Healthcare NHS Trust key for medicine-related NICE Technology ppraisals. has been approved by the Drugs and Therapeutics Committee as recommended within
More information29 August 2016 Page 1 of 7. How does the NHS board decide which new medicines to make available for patients?
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available for use in an NHS board only after it has been: accepted for use in the NHSScotland
More informationCancer Therapy Update in 2017
Cancer Therapy Update in 2017 Editor: Le Wang, M.D., Ph.D Medical Oncology and Hematology (Board-Certified) Ibrutinib (Imbruvica) Pharmacyclics 1 /19/2017 Lymphoma Marginal Zone Lymphoma (MZL), Relapsed/Refractory
More informationSpecialty Pharmacy Pipeline
Specialty Pharmacy Pipeline Drugs to Watch Anticipated Launches Q1 Q2 2017 Atopic Dermatitis Dupixent (dupilumab) Subcutaneous injection Regeneron Pharmaceuticals/Sanofi moderate-to-severe atopic dermatitis
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic Agents Original Policy Date: January 16, 2015 Subject: Opdivo Page:
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic nts Original Policy Date: January 16, 2015 Subject: Opdivo Page: 1 of
More informationPegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine TA440
This spreadsheet is updated monthly and enables self-audit of a medicines for All guidelines refer to adults unless indicated. No copyright is asserted on this Technology appraisal (TA) Titles are hyperlinks
More informationMedicare Part C Medical Coverage Policy
Step Therapy: Part B Medications Origination: December 19, 2018 Review Date: December 19, 2018 Next Review: December 2020 Medicare Part C Medical Coverage Policy DESCRIPTION OF PROCEDURE SERVICE Step Therapy
More informationCortellis Drugs to Watch 2017
Cortellis Drugs to Watch 2017 The 2017 edition of the annual Drugs to Watch report forecasts that eight new drugs will enter the market in 2017 and achieve blockbuster sales of >$1 billion by 2021, as
More informationMedicine Condition being treated NHSGGC Decision Date of decision. 18 June 2018 Page 1 of 5
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available in a health board only after it has been: accepted for use in by the Scottish Medicines
More informationDescription of Commitment
AbbVie U.S. Postmarketing s Table: Name of ANDROGEL (testosterone gel) CREON (pancrelipase) CREON (pancrelipase) / 022309 and 021015 20725 20725 125057/0 125057/114 Description of A randomized, double-blind,
More informationDirectorate General of Health Services Office of Drugs Controller General (India) (Biological Division)
Directorate General of Health Services Office of Drugs Controller General (India) (Biological Division) List of r-dna drug products approved in the country (Form 45 and 45A) from 1 st Jan 2015 to 30 th
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 6 Last Review Date: September 15, 2017 Keytruda Description Keytruda
More informationSpecialty Pipeline Update
CLINICAL SOLUTIONS Drug Insights > December 2015 Specialty Pipeline Update New Drug Information Alecensa (alectinib): The Food and Drug Administration (FDA) approved Genentech s orally administered ALK
More informationCommissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
More informationSpecialty Pipeline Update
CLINICAL SOLUTIONS Drug Insights > September 2015 Specialty Pipeline Update New Drug Information Xuriden (uridine triacetate): The Food and Drug Administration (FDA) approved Wellstat Therapeutics oral
More informationOncology Pipeline Analytics
Oncology Pipeline Analytics Trials, Drug Classes, Indications, Correlations and Strategies Report Brochure O n c o l o g y P i p e l i n e A n a l y t i c s Greystone Research Associates is pleased to
More informationWell Informed. Utilization Program Updates to Promote Guideline Adherence. Effective January 1, 2018:
Q3 2 0 1 7 As we continue our rapid growth under the ownership of The Carlyle Group, we have a lot of exciting news to share. This edition details upcoming changes to our 2018 drug utilization programs
More informationOpen and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona
Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Solid Tumor: USON 15180 / A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab
More informationNew Mexico Health Connections Drug Safety Updates. Drug Safety Updates Q Route of Administration. Action. Brand Name Generic Name Indications
Q4 2017 Advair Diskus salmeterol Asthma, COPD inhaler Advair HFA salmeterol Asthma inhaler Airduo Respiclick salmeterol Asthma inhaler Alecensa alectinib Non-Small Cell Lung Cancer Genentech announced
More informationBiologics for Autoimmune Diseases
Biologics for Autoimmune Diseases Goal(s): Restrict use of biologics to OHP funded conditions and according to OHP guidelines for use. Promote use that is consistent with national clinical practice guidelines
More informationSpecialty Pipeline Update
Specialty Pipeline Update D Drug Insights > March 2016 New drug information Odefsey (emtricitabine, tenofovir alafenamide, rilpivirine): The Food and Drug Administration (FDA) approved Gilead s combination
More informationMarch 2017 Pharmacy & Therapeutics Committee Decisions
UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed
More information1-3 Promising New Agents 4 Projected Generic Entry 4 Investigational Indications 4 FDA Updates. Promising New Agents. Drug Name: Atezolizumab
April 2016 PIPELINE TR x ENDS PIPELINE TR x ENDS is produced by the University of Massachusetts Medical School s Clinical Pharmacy Services division and distributed to our clients annually. 1-3 Promising
More informationAnticipated Launches Q Q2 2019
Anticipated Launches Q1 2019 Q2 2019 Disease Prevalence Multiple Sclerosis (MS) Mayzent (siponimod) oral Novartis secondary progressive multiple sclerosis (SPMS) Pending U.S. Food Drug (FDA) 03/25/2019
More information04 September 2017 Page 1 of 6
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available in a health board only after it has been: accepted for use in by the Scottish Medicines
More informationMagellan Rx. A smarter approach to pharmacy benefits management
Magellan Rx A smarter approach to pharmacy benefits management Presented by: Cheri Caruso, VP of Sales, Magellan Rx Management Bryce Canfield, VP, Client Development, GoodRx A unique vision of care We
More informationNew Developments in Cancer Treatment. Dulcinea Quintana, MD
New Developments in Cancer Treatment Dulcinea Quintana, MD Mortality Rates Goals of treatment 1 Cure Goal of treatment 2 Prolong life Goals of treatment 3 Improve Quality of Life Goals of treatment 4
More informationWell Informed. A Comprehensive Approach to Pain Management. Pain Guardian
Q1 2 0 1 7 Well Informed A Comprehensive Approach to Pain Management Use of opioids is common and necessary to support treatment for a wide variety of health related issues; however, the use of opioid
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 7 Last Review Date: December 8, 2017 Keytruda Description Keytruda
More information10 Musculoskeletal and Joint Diseases
Recommendations from the Lothian Formulary Committee (FC) following Scottish Medicines Consortium (SMC) advice, NICE MTA advice, (FAF3) unlicensed and off-label medicines and (FAF2) medicines not considered
More informationThe Medical Letter. on Drugs and Therapeutics
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07/15 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationCorporate Medical Policy
Corporate Medical Policy Monoclonal Antibodies for Non-Hodgkin Lymphoma and Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: monoclonal_antibodies_for_non_hodgkin_lymphoma_acute_myeloid_leukemia
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: September 20, 2018 Keytruda Description Keytruda
More informationDrug Class Review Monograph GPI Class 12 Antivirals
Drug Class Review Monograph GPI Class 12 Antivirals Review Time Frame: 02/2016 04/2017 Previous Class Review: 05/2016 Background: Antiviral agents are used to treat infections caused by viruses, including,
More informationClinical Therapeutic Intelligence Report: Year in Review
Clinical Therapeutic Intelligence Report: Year in Review Last year marked a productive year for oncology drug research and development with ten new oncology drugs coming to market two of which were granted
More informationClinical Overview of Innovative New Drug Approvals in 2017
Reddy: Clinical Overview of Innovative New Drug Approvals in 2017 4225 International Journal of Pharmaceutical Sciences and Nanotechnology Review Article Clinical Overview of Innovative New Drug Approvals
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: ERX.SPA.302 Effective Date:
Clinical Policy: (Opdivo) Reference Number: ERX.SPA.302 Effective Date: 03.01.19 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationRevlimid. Revlimid (lenalidomide) Description. Section: Prescription Drugs Effective Date: October 1, 2016
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.47 Subject: Revlimid Page: 1 of 7 Last Review Date: September 15, 2016 Revlimid Description Revlimid
More informationHepatitis C Virus Management
Hepatitis C Virus Management FDA-Approved Medications Hepatitis C is caused by a virus and results in liver inflammation, which can lead to advanced liver disease and/or liver cancer. An estimated 3 to
More informationThe Patent Trial and Appeal Board ( Board ) has heard numerous petitions for
BIOTECH BUZZ Biotech Litigation APRIL 2018 Contributor: Laura W. Smalley Recent Sandoz Inc. Petitions against AbbVie Result in Grant of Inter Partes Review of Patents Covering Methods of Treatment using
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 27 th Prioritization 2 nd quarter 2016 General Information, efficacy and safety data Nicole Grössmann Claudia Wild Please note: Within this document
More informationVectibix (panitumumab) will be considered medically necessary when all of the following criteria are met:
What s New Medical Pharmaceutical Policy November 2017 Updates MBP 40.0 Orencia IV (abatacept)- New Indication Orencia IV (abatacept) will be considered medically necessary when all of the following criteria
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07.15 Last Review Date: 01.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationRevlimid. Revlimid (lenalidomide) Description. Section: Prescription Drugs Effective Date: July 1, 2015
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.47 Subject: Revlimid Page: 1 of 6 Last Review Date: June 19, 2015 Revlimid Description Revlimid (lenalidomide)
More informationNew Drug Update 2017 Brooke Roe, PharmD, BCPS Katie Wenstrom, PharmD
New Drug Update 2017 Brooke Roe, PharmD, BCPS Katie Wenstrom, PharmD Objectives: 1. Identify significant therapeutic agents that were granted U.S. Food and Drug Administration approval in the past year
More informationClinical Therapeutic Intelligence Report: 2015 Year in Review
Clinical Therapeutic Intelligence Report: 2015 Year in Review This issue highlights the many ground-breaking therapies approved by the U.S. Food and Drug Administration over the course of 2015. Highlights
More information2. Treatment of patients with metastatic, squamous NSCLC progressing after platinumbased
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.39 Subject: Gilotrif Page: 1 of 5 Last Review Date: September 15, 2017 Gilotrif Description Gilotrif
More informationTarceva. Tarceva (erlotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.82 Subject: Tarceva Page: 1 of 5 Last Review Date: June 22, 2018 Tarceva Description Tarceva (erlotinib)
More informationLondon Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.
February 2013 London Cancer New s Group (LCNDG) Work Plan for the London Cancer s Fund London Cancer s Fund List This Cancer s Fund (CDF) list of medicines and s is in two parts. 1. The standard list of
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: November 30, 2018 Keytruda Description Keytruda
More informationUpdates in Hematology
Updates in Hematology Disclosure Received honoraria on Speaker s Bureau for Pfizer and Takeda Oncology Received honoraria for Advisory Board of Pfizer and Lilly Manpreet Chahal, PharmD, PhD Oncology Pharmacist,
More informationGazyva (obinutuzumab)
STRENGTH DOSAGE FORM ROUTE GPID 1000mg/40mL Vial Intravenous 35532 MANUFACTURER Genentech, Inc. INDICATION(S) Gazyva (obinutuzumab) is a CD20- directed cytolytic antibody and is indicated, in combination
More informationLUNCH AND LEARN. May 11, CE Activity Information & Accreditation
LUNCH AND LEARN May 11, 2018 Featured Speaker: Mary Lynn Moody, B.S. Pharm. Assistant Dean for Business Development Clinical Associate Professor Drug Information and Prior Authorization Group Department
More informationChronic Lymphocytic Leukemia Update. Learning Objectives
Chronic Lymphocytic Leukemia Update Ashley Morris Engemann, PharmD, BCOP, CPP Clinical Associate Adult Stem Cell Transplant Program Duke University Medical Center August 8, 2015 Learning Objectives Recommend
More informationCancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
More informationCURRENT STATUS ANTICIPATED APPROVAL WHAT IS THIS DRUG BEING DEVELOPED FOR? PIPELINE DRUG
PIPELINE DRUG CURRENT STATUS ANTICIPATED APPROVAL WHAT IS THIS DRUG BEING DEVELOPED FOR? abemaciclib Eli Lilly Phase 3 2018 CDK4/6 inhibitor for the treatment of hormone-receptor-positive (HR+) metastatic
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 28 th Prioritization 3 rd quarter 2016 General Information, efficacy and safety data Nicole Grössmann Claudia Wild Please note: Within this document
More informationDrug Class Review Targeted Immune Modulators
Drug Class Review Targeted Immune Modulators Final Update 5 Report June 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationDRAFT. Therapeutic Class Code: D6A, S2J, S2M, S2Q, Z2U, Z2Z, S2Z, L1A, S2V, Z2V, D6K Therapeutic Class Description: Injectable Immunomodulators
AFT Therapeutic Class Code: D6A, S2J, S2M, S2Q, Z2U, Z2Z, S2Z, L1A, S2V, Z2V, D6K Therapeutic Class Description: Injectable Immunomodulators Medication Generic Code Number(s) NDC Number(s) Actemra SQ 35486
More informationAfinitor. Afinitor and Afinitor Disperz (everolimus) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.62 Subject: Afinitor Page: 1 of 7 Last Review Date: June 22, 2017 Afinitor Description Afinitor and
More informationCosentyx. Cosentyx (secukinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx
More informationChanges from Third Quarter Flash Report for the Fiscal Year ending March 2015 announced on February 3, 2015 *1: Marketing authorization of Onoact 150
Annual Flash Report (unaudited) Fiscal Year ended March 31, 2015 Supplemental Information Status of Development Pipeline as of May 12, 2015 I. Main Pipelines Other than ONO-4538 ⅰ. Developments Status
More informationCLINICAL TRIALS ACC. Jul 2016
CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
More informationFebruary - March - April 2017 Selected Content Updates. Approved to treat chorea associated with Huntington disease
Selected Content for Customer Newsletter and Content Link February March April 2017 FDA Approvals new monographs and patient medication instructions Abaloparatide (Tymlos ) Approved to reduce the risk
More informationOral Chemotherapy Agents
Oral Chemotherapy Agents NEW ADVANCES IN TARGETED THERAPY, OVERCOMING BARRIERS AND PROMOTING ADHERENCE KATIE SIAS, PHARMD CLINICAL PHARMACY COORDINATOR HEMATOLOGY/ONCOLOGY MIDMICHIGAN MEDICAL CENTER -
More informationCLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Rituxan (rituximab) Policy Number: MP-031-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Issue Date: 11/01/2017
More informationCover story. Austedo Ingrezza Brineura Alunbrig Rydapt Tymlos Imfinzi Radicava Kevzara Baxdela Bevyxxa
Cover story Downloaded via 148.251.232.83 on March 9, 2019 at 14:34:33 (UTC). See https://pubs.acs.org/sharingguidelines for options on how to legitimately share published articles. Trulance Parsabiv Emflaza
More informationPrescription Benefit Management. Eric Cannon, PharmD, FAMCP
Prescription Benefit Management Eric Cannon, PharmD, FAMCP Agenda Drugs as a Share of Health Spending Top Drugs of 2016 Management Interventions and Strategies Specialty Pharmacy, Generics and Biologics
More informationOncology Market Forecast To 2013
Oncology Market Forecast To 2013 How do you uncover the threats and opportunities that your oncology drug will face this year, next year and each year after that? Our new report answers your questions
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.HNMC.27 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC
Clinical Policy: (Opdivo) Reference Number: CP.HNMC.27 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy for
More informationClinical Research Institute HUCH Sponsored, fully signed Clinical Trial Agreements (except grants)
, fully signed Clinical Trial Agreements (except grants) Sponsor Full name of the Hospital clinic where the is details of the January x x January x NightstaRx Ltd A Randomised, Open Label, Outcomes-Assessor
More informationCancer Drug Pipeline Information for Patient Advocacy Groups. Breast Cancer. Route of Administration. Brand Name Generic Name Manufacturer Indication
Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the will be submitted to the pcodr program. The use of this information is solely intended for informational
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 5 Last Review Date: June 24, 2016 Keytruda Description Keytruda (pembrolizumab)
More informationClinical Policy: Idelalisib (Zydelig) Reference Number: ERX.SPA.269 Effective Date:
Clinical Policy: (Zydelig) Reference Number: ERX.SPA.269 Effective Date: 12.01.18 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationDeveloping a Oncology Treatment Resource for Claims-Based Research: Innovation with Medications
Developing a Oncology Treatment Resource for Claims-Based Research: Innovation with Medications Donna R. Rivera, PharmD., MSc. Scientific Project Officer and Pharmacist Surveillance Informatics Branch
More informationSummary of Research and Writing Activities in Oncology
Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,
More informationZydelig. Zydelig (idelalisib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.49 Subject: Zydelig Page: 1 of 6 Last Review Date: June 22, 2017 Zydelig Description Zydelig (idelalisib)
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement until 6/30/2019. Nivolumab
Medical Manual Approved Revised: Do Not Implement until 6/30/2019 Nivolumab NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationMerck Pipeline. November 1, 2017
Merck Pipeline November 1, 2017 Lead-in Language The chart below reflects the Company s research pipeline as of November 1, 2017. Candidates shown in Phase 3 include specific products and the date such
More informationMerck Pipeline. August 1, 2018
Merck Pipeline August 1, 2018 Lead-in Language The chart below reflects the Company s research pipeline as of August 1, 2018. Candidates shown in Phase 3 include specific products and the date such candidate
More informationJanssen Hematologic Malignancy Portfolio
Janssen Hematologic Malignancy Portfolio Recorded Webcast: Update for Analysts and Investors January 216 Oncology 1 Safe Harbor Statement This webcast contains "forward-looking statements" as defined in
More informationPRECISION CANCER MEDICINE DR. VANESSA DICKEY TORRANCE MEMORIAL PHYSICIAN NETWORK CANCER CARE ASSOCIATES
PRECISION CANCER MEDICINE DR. VANESSA DICKEY TORRANCE MEMORIAL PHYSICIAN NETWORK CANCER CARE ASSOCIATES REAL PATIENT; ANN (ALIAS) 63 year old woman who smoked for 25 years, quit 15 years ago. Complained
More informationCancer: Can we Afford the Cure? Current Trends in Oncology Treatment
Cancer: Can we Afford the Cure? Current Trends in Oncology Treatment Julie Kennerly-Shah, PharmD, MS, MHA, BCPS May 30, 2018 The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer
More informationONCOLOGY DRUG UPDATE 3/31/2017 DISCLOSURES OBJECTIVES OUTLINE QUIZ DRUG PIPELINE. I do not have any conflicts of interest or disclosures to make
DISCLOSURES I do not have any conflicts of interest or disclosures to make ONCOLOGY DRUG UPDATE Mark Wagner, PharmD, BCOP April 8 th, 2017 2 OBJECTIVES Identify the new medications that were approved in
More informationList of Recombinant DNA based Drugs Approved in the Country (Form-45) 1st Jan st Dec 2013
S.No. 1 Name of the firm Ferring Date of Approval 4-Apr-10 License No. Import-450/10 2 G.C.Chemie 23-Jun-10 IMP-572/10 3 R.K. Medicare 9-Sep-10 IMP-783/10 4 5 List of Recombinant DNA based Drugs Approved
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement Until 3/2/19. Nivolumab (Intravenous)
Nivolumab (Intravenous) NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3734-XX Opdivo 240
More informationTNF Inhibitors: Lessons From Immunogenicity
TNF Inhibitors: Lessons From Immunogenicity Edward Keystone, MD, FRCP(C) Professor of Medicine University of Toronto Toronto, Canada Edward Keystone, MD FRCP(C) Disclosures Sources of Funding for Research:
More informationAnnual Flash Report (unaudited) Fiscal Year ended March 31, 2017
Annual Flash Report (unaudited) Fiscal Year ended March 31, 2017 Supplemental nation Status of Development Pipeline as of May 8, 2017. Main Status of Development Pipelines (Oncology) 1. Development Status
More informationCrisis Investing: Profits From a Diabetes Drug About to Get Approved Crisis Investing: Profits From a Diabetes Drug About to Get Approved
Crisis Investing: Profits From a Diabetes Drug About to Get Approved A Special Research Report from Bret Jensen's Biotech Gems Lexicon Pharmaceuticals (Nasdaq: LXRX): tackling one of America s biggest
More information